Trial reportBMC neurology2016
A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.
Trial report in BMC neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Exploratory Evaluation of Hydrogen-Rich Water Therapy for Keloid Management: A Double-Blinded Randomized Pilot Trial.Aesthetic plastic surgery · 2026Trial
- Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment.Current Alzheimer research · 2018Trial
- Effects of perioperative hydrogen inhalation on brain edema and prognosis in patients with glioma.Frontiers in neurology · 2025Article
- Role and mechanism of molecular hydrogen in the treatment of Parkinson's diseases.Frontiers in neuroscience · 2025Review
- Recent advances in the application of gasotransmitters in spinal cord injury.Journal of nanobiotechnology · 2024Review
- Redox-Mechanisms of Molecular Hydrogen Promote Healthful Longevity.Antioxidants (Basel, Switzerland) · 2023Review
- Molecular Hydrogen: an Emerging Therapeutic Medical Gas for Brain Disorders.Molecular neurobiology · 2023Review
- Drinking hydrogen water improves photoreceptor structure and function in retinal degeneration 6 mice.Scientific reports · 2022Article
- Role of Molecular Hydrogen in Ageing and Ageing-Related Diseases.Oxidative medicine and cellular longevity · 2022Review
- Neuroprotective Effects of Molecular Hydrogen: A Critical Review.Neuroscience bulletin · 2021Review
- Molecular Hydrogen: A Promising Adjunctive Strategy for the Treatment of the COVID-19.Frontiers in medicine · 2021Review
- Effect of hydrogen-rich water on the Nrf2/ARE signaling pathway in rats with myocardial ischemia-reperfusion injury.Journal of bioenergetics and biomembranes · 2019Article
- Antioxidants Attenuate Oxidative Stress-Induced Hidden Blood Loss in Rats.Turkish journal of haematology : official journal of Turkish Society of Haematology · 2017Article
- Molecular hydrogen in the treatment of acute and chronic neurological conditions: mechanisms of protection and routes of administration.Journal of clinical biochemistry and nutrition · 2017Review
- Erratum to: A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.BMC neurology · 2017Article
- Proposal of next-generation medical care "Mega-hydrogen Therapy".Medical gas researchReview
- The overlooked benefits of hydrogen-producing bacteria.Medical gas researchReview
Corrections and comments
- Erratum issued
Authors and funding
22 authors at 14 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOur previous randomized double-blind study showed that drinking hydrogen (H2) water for 48 weeks significantly improved the total Unified Parkinson's Disease Rating Scale (UPDRS) score of Parkinson's disease (PD) patients treated with levodopa. We aim to confirm this result using a randomized double-blind placebo-controlled multi-center trial.
methodsChanges in the total UPDRS scores from baseline to the 8(th), 24(th), 48(th), and 72(nd) weeks, and after the 8(th) week, will be evaluated. The primary endpoint of the efficacy of this treatment in PD is the change in the total UPDRS score from baseline to the 72(nd) week. The changes in UPDRS part II, UPDRS part III, each UPDRS score, PD Questionnaire-39 (PDQ-39), and the modified Hoehn and Yahr stage at these same time-points, as well as the duration until the protocol is finished because additional levodopa is required or until the disease progresses, will also be analyzed. Adverse events and screening laboratory studies will also be examined. Participants in the hydrogen water group will drink 1000 mL/day of H2 water, and those in the placebo water group will drink normal water. One-hundred-and-seventy-eight participants with PD (88 women, 90 men; mean age: 64.2 [SD 9.2] years, total UPDRS: 23.7 [11.8], with levodopa medication: 154 participants, without levodopa medication: 24 participants; daily levodopa dose: 344.1 [202.8] mg, total levodopa equivalent dose: 592.0 [317.6] mg) were enrolled in 14 hospitals and were randomized. DISCUSSION: This study will confirm whether H2 water can improve PD symptoms.
trial registrationUMIN000010014 (February, 13, 2013).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.